Volume 127, Issue 5, Pages 1347-1355 (November 2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients  Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel E. Sentjens, José L. Calleja, Xavier Forns, Andreas Erhardt, Jens Crönlein, Ricardo L. Chaves, Chan-Loi Yong, Gerhard Nehmiz, Gerhard G. Steinmann  Gastroenterology  Volume 127, Issue 5, Pages 1347-1355 (November 2004) DOI: 10.1053/j.gastro.2004.08.002 Copyright © 2004 American Gastroenterological Association Terms and Conditions

Figure 1 Virologic efficacy of 25 mg BILN 2061 twice daily (Amplicor assay) in patients with minimal liver fibrosis: study 1. Dotted lines represent control patients, solid lines represent treated patients, upper and lower intermittent lines represent the upper and lower limits of detection of the Amplicor assay, black triangles represent administration of BILN 2061, squares represent genotype 1a, and circles represent genotype 1b. Gastroenterology 2004 127, 1347-1355DOI: (10.1053/j.gastro.2004.08.002) Copyright © 2004 American Gastroenterological Association Terms and Conditions

Figure 2 Virologic efficacy of 200 mg BILN 2061 twice daily (Amplicor assay) in pretreated and drug-naive patients with minimal liver fibrosis: study 1. Dotted lines represent control patients, solid lines represent treated patients, circles represent drug-naive patients (na), squares represent patients who did not respond to anti-HCV therapy (NR), upper and lower intermittent lines represent the upper and lower limits of detection of the Amplicor assay, and black triangles represent administration of BILN 2061. Gastroenterology 2004 127, 1347-1355DOI: (10.1053/j.gastro.2004.08.002) Copyright © 2004 American Gastroenterological Association Terms and Conditions

Figure 3 Virologic efficacy of 500 mg BILN 2061 twice daily (Amplicor assay) in patients with minimal liver fibrosis: study 1. Dotted lines represent control patients, solid lines represent treated patients, circles represent drug-naive patients (na), squares represent patients who did not respond to anti-HCV therapy (NR), upper and lower intermittent lines represent the upper and lower limits of detection of the Amplicor assay, and black triangles represent administration of BILN 2061. Gastroenterology 2004 127, 1347-1355DOI: (10.1053/j.gastro.2004.08.002) Copyright © 2004 American Gastroenterological Association Terms and Conditions